CXCL1 and CXCL6 Are Potential Predictors for HCC Response to TACE

Distinct immune patterns of hepatocellular carcinoma (HCC) may have prognostic implications in the response to transarterial chemoembolization (TACE). Thus, we aimed to exploratively analyze tumor tissue of HCC patients who do or do not respond to TACE, and to identify novel prognostic biomarkers predictive of response to TACE. We retrospectively included 15 HCC patients who had three consecutive TACE between January 2019 and November 2019. Eight patients had a response while seven patients had no response to TACE. All patients had measurable disease according to mRECIST. Corresponding tumor tissue samples were processed for differential expression profiling using NanoString nCounter® PanCancer immune profiling panel. Immune-related pathways were broadly upregulated in TACE responders. The top differentially regulated genes were the upregulated CXCL1 (log2fc 4.98, Benjamini–Hochberg (BH)-p < 0.001), CXCL6 (log2fc 4.43, BH-p = 0.016) and the downregulated MME (log2fc −4.33, BH-p 0.001). CD8/T-regs was highly increased in responders, whereas the relative number of T-regs to tumor-infiltrating lymphocytes (TIL) was highly decreased. We preliminary identified CXCL1 and CXCL6 as candidate genes that might have the potential to serve as therapeutically relevant biomarkers in HCC patients. This might pave the way to improve patient selection for TACE in HCC patients beyond expert consensus.

[1]  J. Bruix,et al.  BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. , 2021, Journal of hepatology.

[2]  J. Bruix,et al.  Systemic treatment of hepatocellular carcinoma. An EASL position paper. , 2021, Journal of hepatology.

[3]  T. Vogl,et al.  Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial , 2021, Hepatology International.

[4]  H. Goebel,et al.  NanoString technology distinguishes anti‐TIF‐1γ+ from anti‐Mi‐2+ dermatomyositis patients , 2021, Brain pathology.

[5]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[6]  Jhin Jieh Lim,et al.  JAK/STAT signaling in hepatocellular carcinoma , 2020, Hepatic oncology.

[7]  Hui Zhang,et al.  Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study. , 2019, Journal of hepatology.

[8]  T. de Baère,et al.  Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. , 2019, Cancer treatment reviews.

[9]  P. Schirmacher,et al.  Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  J. Marquardt,et al.  Immunotherapy of Hepatocellular Carcinoma , 2018, Oncology Research and Treatment.

[11]  K. Eichler,et al.  Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study , 2018, RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren.

[12]  M. Lucey,et al.  Multidisciplinary Management of Hepatocellular Carcinoma Improves Access to Therapy and Patient Survival , 2017, Journal of clinical gastroenterology.

[13]  Z. Li,et al.  Elevated CXCL1 increases hepatocellular carcinoma aggressiveness and is inhibited by miRNA-200a , 2016, Oncotarget.

[14]  Andrew D. Rouillard,et al.  Enrichr: a comprehensive gene set enrichment analysis web server 2016 update , 2016, Nucleic Acids Res..

[15]  S. Ahn,et al.  Addition of tumor multiplicity improves the prognostic performance of the hepatoma arterial‐embolization prognostic score , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[16]  A. Teufel,et al.  Tumor‐infiltrating, interleukin‐33–producing effector‐memory CD8+ T cells in resected hepatocellular carcinoma prolong patient survival , 2015, Hepatology.

[17]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[18]  B. Sangro,et al.  Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Heinzl,et al.  How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. , 2014, Journal of hepatology.

[20]  Wenqing Tang,et al.  HIF-1α Plays a Role in the Chemotactic Migration of Hepatocarcinoma Cells Through the Modulation of CXCL6 Expression , 2014, Cellular Physiology and Biochemistry.

[21]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[22]  A. Burroughs,et al.  A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  Edward Y. Chen,et al.  Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool , 2013, BMC Bioinformatics.

[24]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[25]  Kellie J. Archer,et al.  High-throughput assessment of CpG site methylation for distinguishing between HCV-cirrhosis and HCV-associated hepatocellular carcinoma , 2010, Molecular Genetics and Genomics.

[26]  Riccardo Lencioni,et al.  Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma , 2010, Seminars in liver disease.

[27]  Y. Chawla,et al.  Immunology of hepatocellular carcinoma. , 1991, The Italian journal of gastroenterology.